Detail akcie Emmaus Life Sci Rg online

Business Summary: Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, marketing and sale of treatments and therapies, primarily for rare and orphan diseases. Its lead product, Endari (prescription grade L-glutamine oral powder) helps to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003, and ELS002. The Company, through Kainos Medicine, Inc. (Kainos), has a license in the territory encompassing the United States, the United Kingdom, and the European Union to patent rights, know-how, and other intellectual property relating to Kainos’s IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, including leukemia, lymphoma, and solid tumor cancers. The Company has also developed chondrocyte and osteoblast cell sheets using human mesenchymal stem cells.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Emmaus Life Sciences Inc revenues decreased 36% to $8.6M. Net loss increased 18% to $5.5M. Revenues reflect Endari segment decrease of 61% to $5.1M, Other segment decrease of 54% to $195K. Higher net loss reflects Loss on debt extinguishment increase from $1M (income) to $672K (expense), Interest Expense increase of 15% to $4.9M (expense).